{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:10:24Z","timestamp":1787674224382,"version":"build-2784847793"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s10067-023-06779-2","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T01:02:04Z","timestamp":1695258124000},"page":"521-526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Factors associated with sarcopenia in Japanese patients with rheumatoid arthritis: results from the IORRA cohort study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6757-897X","authenticated-orcid":false,"given":"Masanori","family":"Nakayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7771-2813","authenticated-orcid":false,"given":"Takefumi","family":"Furuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1652-7769","authenticated-orcid":false,"given":"Eisuke","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2850-326X","authenticated-orcid":false,"given":"Eiichi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9066-2005","authenticated-orcid":false,"given":"Katsunori","family":"Ikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8453-6731","authenticated-orcid":false,"given":"Hisashi","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-2603","authenticated-orcid":false,"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"6779_CR1","doi-asserted-by":"publisher","first-page":"e0169548","DOI":"10.1371\/journal.pone.0169548","volume":"12","author":"C Beaudart","year":"2017","unstructured":"Beaudart C, Zaaria M, Pasleau F, Reginster JY, Bruyere O (2017) Health outcomes of sarcopenia: a systematic review and meta-analysis. PLoS ONE 12:e0169548. https:\/\/doi.org\/10.1371\/journal.pone.0169548","journal-title":"PLoS ONE"},{"key":"6779_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.maturitas.2020.01.004","volume":"133","author":"F Petermann-Rocha","year":"2020","unstructured":"Petermann-Rocha F, Chen M, Gray SR, Ho FK, Pell JP, Celis-Morales C (2020) Factors associated with sarcopenia: a cross-sectional analysis using UK Biobank. Maturitas 133:60\u201367. https:\/\/doi.org\/10.1016\/j.maturitas.2020.01.004","journal-title":"Maturitas"},{"key":"6779_CR3","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1136\/ard.2003.009530","volume":"63","author":"T Sokka","year":"2004","unstructured":"Sokka T, Hakkinen A, Krishnan E, Hannonen P (2004) Similar prediction of mortality by the health assessment questionnaire in patients with rheumatoid arthritis and the general population. Ann Rheum Dis 63:494\u2013497. https:\/\/doi.org\/10.1136\/ard.2003.009530","journal-title":"Ann Rheum Dis"},{"key":"6779_CR4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/14397595.2018.1510565","volume":"29","author":"M Torii","year":"2019","unstructured":"Torii M, Hashimoto M, Hanai A, Fujii T, Furu M, Ito H et al (2019) Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis. Mod Rheumatol 29:589\u2013595. https:\/\/doi.org\/10.1080\/14397595.2018.1510565","journal-title":"Mod Rheumatol"},{"key":"6779_CR5","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1111\/1756-185X.13335","volume":"21","author":"M Tada","year":"2018","unstructured":"Tada M, Yamada Y, Mandai K, Hidaka N (2018) Matrix metalloprotease 3 is associated with sarcopenia in rheumatoid arthritis\u2014results from the CHIKARA study. Int J Rheum Dis 21:1962\u20131969. https:\/\/doi.org\/10.1111\/1756-185X.13335","journal-title":"Int J Rheum Dis"},{"key":"6779_CR6","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/ggi.13747","volume":"19","author":"T Mochizuki","year":"2019","unstructured":"Mochizuki T, Yano K, Ikari K, Okazaki K (2019) Sarcopenia-associated factors in Japanese patients with rheumatoid arthritis: a cross-sectional study. Geriatr Gerontol Int 19:907\u2013912. https:\/\/doi.org\/10.1111\/ggi.13747","journal-title":"Geriatr Gerontol Int"},{"key":"6779_CR7","doi-asserted-by":"publisher","first-page":"140e145","DOI":"10.1016\/j.afos.2021.11.002","volume":"7","author":"M Tada","year":"2021","unstructured":"Tada M, Yamada Y, Mandai K, Matsumoto Y, Hidaka N (2021) Osteosarcopenia synergistically increases the risk of falls in patients with rheumatoid arthritis. Osteoporos Sarcopenia 7:140e145. https:\/\/doi.org\/10.1016\/j.afos.2021.11.002","journal-title":"Osteoporos Sarcopenia"},{"key":"6779_CR8","doi-asserted-by":"publisher","first-page":"18e87","DOI":"10.1016\/j.afos.2021.06.002","volume":"7","author":"M Tada","year":"2021","unstructured":"Tada M, Yamada Y, Mandai K, Hidaka N (2021) Screening for sarcopenia and obesity by measuring thigh muscle and fat thickness by ultrasound in patients with rheumatoid arthritis. Osteoporos Sarcopenia 7:18e87. https:\/\/doi.org\/10.1016\/j.afos.2021.06.002","journal-title":"Osteoporos Sarcopenia"},{"key":"6779_CR9","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1080\/14397595.2020.1740411","volume":"31","author":"T Mochizuki","year":"2021","unstructured":"Mochizuki T, Yano K, Ikari K, Okazaki K (2021) Sarcopenia in Japanese younger patients with rheumatoid arthritis: a cross-sectional study. Mod Rheumatol 31:504\u2013505. https:\/\/doi.org\/10.1080\/14397595.2020.1740411","journal-title":"Mod Rheumatol"},{"key":"6779_CR10","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/mr\/roac095","volume":"33","author":"M Torii","year":"2023","unstructured":"Torii M, Itaya T, Minamino H, Katsushima M, Fujita Y, Tanaka H et al (2023) Management of sarcopenia in patients with rheumatoid arthritis. Mod Rheumatol 33:435\u2013440. https:\/\/doi.org\/10.1093\/mr\/roac095","journal-title":"Mod Rheumatol"},{"key":"6779_CR11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jamda.2013.05.018","volume":"14","author":"TK Malmstrom","year":"2013","unstructured":"Malmstrom TK, Morley JE (2013) SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc 14:531\u2013532. https:\/\/doi.org\/10.1016\/j.jamda.2013.05.018","journal-title":"J Am Med Dir Assoc"},{"key":"6779_CR12","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1007\/s12603-019-1222-x","volume":"23","author":"N Kurita","year":"2019","unstructured":"Kurita N, Wakita T, Kamitani T, Wada O, Mizuno K (2019) SARC-F validation and SARC-F+EBM derivation in musculoskeletal disease: the SPSS-OK Study. J Nutr Health Aging 23:732\u2013738. https:\/\/doi.org\/10.1007\/s12603-019-1222-x","journal-title":"J Nutr Health Aging"},{"key":"6779_CR13","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.3390\/jcm10163458","volume":"10","author":"HW Yun","year":"2021","unstructured":"Yun HW, Kim CJ, Kim JW, Kim HA, Suh CH, Jung JY (2021) The assessment of muscle mass and function in patients with long-standing rheumatoid arthritis. J Clin Med 10:3458. https:\/\/doi.org\/10.3390\/jcm10163458","journal-title":"J Clin Med"},{"key":"6779_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3109\/14397595.2015.1059983","volume":"26","author":"D Hoshi","year":"2016","unstructured":"Hoshi D, Tanaka E, Igarashi A, Inoue E, Kobayashi A, Sugimoto N et al (2016) Profiles of EQ-5D utility scores in the daily practice of Japanese patients with rheumatoid arthritis; analysis of the IORRA database. Mod Rheumatol 26:40\u201345. https:\/\/doi.org\/10.3109\/14397595.2015.1059983","journal-title":"Mod Rheumatol"},{"key":"6779_CR15","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1080\/14397595.2018.1481727","volume":"29","author":"M Nakayama","year":"2019","unstructured":"Nakayama M, Furuya T, Inoue E, Tanaka E, Ikari K, Nakajima A et al (2019) Factors associated with decreasing serum 25(OH)D among Japanese patients with rheumatoid arthritis: results from the IORRA cohort study. Mod Rheumatol 29:430\u2013435. https:\/\/doi.org\/10.1080\/14397595.2018.1481727","journal-title":"Mod Rheumatol"},{"key":"6779_CR16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.afos.2020.04.003","volume":"6","author":"M Nakayama","year":"2020","unstructured":"Nakayama M, Furuya T, Inoue E, Tanaka E, Ikari K, Taniguchi A et al (2020) Factors associated with osteoporosis medication use in Japanese patients with rheumatoid arthritis: results from the Institute of Rheumatology Rheumatoid Arthritis cohort study. Osteoporos Sarcopenia 6:82\u201387. https:\/\/doi.org\/10.1016\/j.afos.2020.04.003","journal-title":"Osteoporos Sarcopenia"},{"key":"6779_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2019.1660028","volume":"30","author":"H Yamanaka","year":"2020","unstructured":"Yamanaka H, Tanaka E, Nakajima A, Furuya T, Ikari K, Taniguchi A et al (2020) A large observational cohort study of rheumatoid arthritis, IORRA: providing context for today\u2019s treatment options. Mod Rheumatol 30:1\u20136. https:\/\/doi.org\/10.1080\/14397595.2019.1660028","journal-title":"Mod Rheumatol"},{"key":"6779_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11657-021-00982-x","volume":"16","author":"M Nakayama","year":"2021","unstructured":"Nakayama M, Furuya T, Inoue E, Tanaka E, Ikari K, Yamanaka H et al (2021) Vitamin D deficiency is a risk factor for new fractures in Japanese postmenopausal women with rheumatoid arthritis: results from the IORRA cohort study. Arch Osteoporos 16:119. https:\/\/doi.org\/10.1007\/s11657-021-00982-x","journal-title":"Arch Osteoporos"},{"key":"6779_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10067-021-05938-7","volume":"41","author":"T Furuya","year":"2022","unstructured":"Furuya T, Oh K, Ikari K, Inoue E, Tanaka E, Yamanaka H et al (2022) Factors associated with frailty in Japanese patients with rheumatoid arthritis: results from the Institute of Rheumatology Rheumatoid Arthritis cohort study. Clin Rheumatol 41:405\u2013410. https:\/\/doi.org\/10.1007\/s10067-021-05938-7","journal-title":"Clin Rheumatol"},{"key":"6779_CR20","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1093\/mr\/roab130","volume":"32","author":"T Furuya","year":"2022","unstructured":"Furuya T (2022) Clinical observations of osteoporosis in Japanese patients with rheumatoid arthritis. Mod Rheumatol 32:839\u2013845. https:\/\/doi.org\/10.1093\/mr\/roab130","journal-title":"Mod Rheumatol"},{"key":"6779_CR21","doi-asserted-by":"publisher","first-page":"e0277566","DOI":"10.1371\/journal.pone.0277566","volume":"17","author":"E Tanaka","year":"2022","unstructured":"Tanaka E, Inoue E, Shoji A, Nilsson J, Papagiannopoulos C, Dhanda D et al (2022) Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data. PLoS One 17:e0277566. https:\/\/doi.org\/10.1371\/journal.pone.0277566","journal-title":"PLoS One"},{"key":"6779_CR22","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1016\/j.jamda.2021.05.011","volume":"22","author":"SN Voelker","year":"2021","unstructured":"Voelker SN, Michalopoulos N, Maier AB, Reijnierse EM (2021) Reliability and concurrent validity of the SARC-F and its modified versions: a systematic review and meta-analysis. J Am Med Dir Assoc 22:1864\u20131876. https:\/\/doi.org\/10.1016\/j.jamda.2021.05.011","journal-title":"J Am Med Dir Assoc"},{"key":"6779_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/jcsm.12651","volume":"12","author":"A Kitamura","year":"2021","unstructured":"Kitamura A, Seino S, Abe T, Nofuji Y, Yokoyama Y, Amano H et al (2021) Sarcopenia: prevalence, associated factors, and the risk of mortality and disability in Japanese older adults. Cachexia Sarcopenia Muscle 12:30\u201338. https:\/\/doi.org\/10.1002\/jcsm.12651","journal-title":"Cachexia Sarcopenia Muscle"},{"key":"6779_CR24","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/jbmr.4293","volume":"36","author":"NC Harvey","year":"2021","unstructured":"Harvey NC, Orwoll E, Kwok T, Karlsson MK, Rosengren BE, Ribom E et al (2021) Sarcopenia definitions as predictors of fracture risk independent of FRAX\u00ae, falls, and BMD in the Osteoporotic Fractures in Men (MrOS) Study: a meta-analysis. J Bone Miner Res 36:1235\u20131244. https:\/\/doi.org\/10.1002\/jbmr.4293","journal-title":"J Bone Miner Res"},{"key":"6779_CR25","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s10067-020-04929-4","volume":"39","author":"Y Yamada","year":"2020","unstructured":"Yamada Y, Tada M, Mandai K, Hidaka N, Inui K, Nakamura H (2020) Glucocorticoid use is an independent risk factor for developing sarcopenia in patients with rheumatoid arthritis: from the CHIKARA study. Clin Rheumatol 39:1757\u20131764. https:\/\/doi.org\/10.1007\/s10067-020-04929-4","journal-title":"Clin Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06779-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06779-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06779-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T16:20:49Z","timestamp":1704730849000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06779-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["6779"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06779-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,21]]},"assertion":[{"value":"27 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of Tokyo Women\u2019s Medical University (No. 2922-R16).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all patients at entry and before each survey of IORRA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MN has served on speakers\u2019 bureaus for AbbVie Japan GK, Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Chugai Pharmaceutical Co., Daiichi-Sankyo, Nippon Zoki Pharmaceutical Co., Novartis Pharmaceutical K.K., Ono Pharmaceutical Co., and Taisho Pharmaceutical Co.TF has served on speakers\u2019 bureaus for AbbVie Japan GK, Asahi Kasei Corp., Ayumi Pharmaceutical Co., Eli Lilly Japan K.K., Daiichi-Sankyo, Novartis Pharma K.K., and Pfizer Japan Inc.EI has received lecture fees or consulting fees from Bristol Myers Squibb, Eisai Co., Nippontect Systems Co., and Cyberdyne Inc.ET has received lecture fees or consulting fees from AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Bristol Myers Squibb Co., Chugai Pharmaceutical Co., Daiichi-Sankyo, Eisai Co., Eli Lilly Japan K.K., Gilead Sciences, GlaxoSmithKline K.K., Kyowa Pharma Chemical Co., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Mochida Pharmaceutical Co., Nippon Kayaku Co., Pfizer Japan Inc., Takeda Pharmaceutical Co., Teijin Pharma, and Viatris, Japan. ET has received research funding from Pfizer Inc. and UCB Japan Co.KI has received speaker\u2019s fees from Asahi Kasei Pharma Corp., Astellas Pharma Inc., AbbVie Japan GK, Ayumi Pharmaceutical Co., Bristol Myers Squibb, Chugai Pharmaceutical Co., Eisai Co., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Kaken Pharmaceutical Co., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., Teijin Pharma, and UCB Japan Co.HY has received speaker\u2019s fees from Astellas, Bristol Myers Squibb, Eisai, Pfizer, Tanabe-Mitsubishi, Teijin Pharma, and YLBio.MH has received research grants from AbbVie Japan GK, Asahi Kasei Corp., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Bristol Myers Squibb, Chugai Pharmaceutical Co., Eisai Co., Eli Lilly Japan K.K., Kaken Pharmaceutical Co., Mitsubishi Tanabe Pharma Co., Mochida Pharmaceutical Co., Nippon Kayaku Co., Nippon Shinyaku Co., Pfizer Japan Inc., Taisho Pharmaceutical Co., Teijin Pharma, UCB Japan Co., and Viatris Japan. MH has received speaker\u2019s fees from AbbVie Japan GK, Asahi Kasei Corp., Astra Zeneca K.K., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Bristol Myers Squibb, Chugai Pharmaceutical Co., Eisai Co., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Gilead Sciences Inc., Janssen Pharmaceutical K.K., Kissei Pharmaceutical Co., Mitsubishi Tanabe Pharma Co., Mochida Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Taisho Pharmaceutical Co., and Teijin Pharma Ltd. MH is a consultant for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Kissei Pharmaceutical Co., and Teijin Pharma.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest statement"}}]}}